At the moment, Leqembi is administered intravenously at clinics every two weeks, although, in January Eisai and Biogen were ...

The FDA has approved a once-weekly autoinjector version of Eisai’s Leqembi, as the company seeks to grow the drug’s uptake.

Tokyo: Eisai Co., Ltd. and Biogen Inc. have announced that the U.S. Food and Drug Administration (FDA) has approved the ...

Aiming to deliver blockbuster sales of its Alzheimer’s disease-fighting antibody Leqembi in its 2027 fiscal year, Eisai has cleared a key regulatory hurdle in its quest to grow the medicine's reach | ...

Eisai and Biogen have announced that the anti-amyloid beta (Aβ) monoclonal antibody Leqembi (lecanemab) was launched in ...

Cambridge, Mass.-based Biogen entered a licensing agreement with Forward Pharma for the Danish drugmaker's multiple sclerosis treatments.

Four pharmaceutical companies had generic extended-release Adderall on backorder in August at a time of unprecedented demand for the ADHD drug.

Medicare’s proposal that it will cover Alzheimer’s drugs such as Biogen’s embattled Aduhelm only in clinical trials could have a simple but difficult result for the pharma industry: chaos ...